Showing 449 companies
11 - 50 employees

NewAtlantis Labs transforms marine ecosystems into productive natural assets for sustainable ocean conservation.

Biotechnology
DeepTech
Health
1 - 10 employees
Series C+

10x Genomics is creating revolutionary DNA sequencing technology to help researchers better identify subtle variations that are overlooked by technologies that shred biological samples into tiny fragments before sequencing the short stretches and using computers to assembling them into a genome.

23andMe
23andMe
25 jobs
Biotechnology
DeepTech
Health
201 - 1000 employees

23andMe is a human genome research company enabling users to study their ancestry, genealogy, and inherited traits. A startup co-founded by Linda Avey and Anne Wojcicki, the wife of Google co-founder Sergey Brin, 23andMe has plans to make the human genome searchable. Brin, along with Google, gave 23andMe $3.9 million as part of a series A in May of 2007. The company was named after the number of chromosome pairs in humans. They aim to help people understand what their genes mean by indexing them and highlighting significant findings. 23andMe allows its clients/users to study their ancestry, genealogy, and inherited traits. The company also markets to researchers and scientists, for whom they provide neatly categorized and easily searchable data. One reason the Google investment in 23andMe made sense, was that this company could enable the search giant to index another facet of the world's information. With the Biotech and Health Care industries growing rapidly, 23andMe could help Google get and maintain a market hold in these already multi-billion dollar areas.

Biotechnology
DeepTech
Design
Health
11 - 50 employees
Series A

A-Alpha Bio provides cell-based tools for quantitative and high-throughput measurements of protein interactions, accelerating target discovery, library screening, and preclinical drug characterization. A-Alpha Bio's product, AlphaSeq, is a revolutionary cell-based platform technology that will fundamentally change the way that protein interactions are measured. A-Alpha Bio is a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck.

Abbott
Abbott
2,400 jobs
Biotechnology
Deeptech
Food
Health
Manufacturing
5001+ employees

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.

AbbVie
AbbVie
1,577 jobs
Biotechnology
Deeptech
Health
5001+ employees

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need.

Biotechnology
DeepTech
Health
201 - 1000 employees

AbCellera focuses on therapeutic antibodies, screening, choosing, and analyzing millions of naturally produced antibodies to be used as next-generation drug candidates. It specializes in the fields of biotechnology, medicine, and therapeutics.

Biotechnology
DeepTech
Health
51 - 200 employees

Engineering the future of precision radio­therapeutics Abdera is combining advanced antibody engineering with radiotherapeutics to attack cancer in bold new ways.

AbSci
AbSci
7 jobs
Biotechnology
Data and Analytics
DeepTech
Health
Software
51 - 200 employees

AbSci is a synthetic biology company that translates ideas into drugs with a platform technology that reinvents the biopharmaceutical drug discovery process. They custom engineer E. coli to create novel complex biologics in their full length format while simultaneously developing production cell lines. The company is deploying cutting-edge deep learning artificial intelligence to inform their designs, and every day we succeed in achieving things others have dismissed as impossible.

Biotechnology
Data and Analytics
DeepTech
Design
Health
51 - 200 employees

Active Motif Chromeon provides innovative fluorescent reagents for Life Science research applications including several lines of fluorescent chromophores the Chromeo Dyes, RuLabels and Py-Dyes. Chromeo Dye excitation and emission properties match common excitation sources and filter sets, ideal for microscopy and plate-based assays. RuLabels are phosphorescent ruthenium probes that emit strongly polarized light with a long decay time, which enhances sensitivity and reduces background. The Py-Dyes possess unique physical and spectral properties that make conjugation simple, while reatly reducing background. As alternative to organic dyes, a set of bright and biocompatible fluorescent nanoparticles is offered. They represent excellent tools for increasing the sensitivity of your assays.

Biotechnology
DeepTech
Health
201 - 1000 employees

Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers. It was founded in 2009 and headquartered in Seattle, Washington.

Biotechnology
Data and Analytics
DeepTech
Design
Health
51 - 200 employees
Series B

Aera Therapeutics is a biotechnology company that uses its proprietary protein nanoparticle (PNP) delivery platform to help genetic medicines reach their full potential. Aera's platform, which is based on endogenous human proteins, is being developed to address the limitations of current delivery technologies and to extend the reach of genetic medicines to different tissues and applications, thereby benefiting more patients across a broader range of disease areas. In addition, Aera's licensed technology includes a therapeutic enzyme platform based on the discovery of novel, compact, and programmable gene-editing enzymes.